Mr. Hugh Rogers reports

BIONXT ANNOUNCES SHARES FOR DEBT SETTLEMENT

Bionxt Solutions Inc. has proposed to enter into a debt settlement agreement with certain arm's-length creditors to settle an aggregate outstanding debt of $2,704,000, comprising a principal amount of $2.6-million and accrued interest of $104,000 pursuant to 8 per cent convertible debentures issued by the company on Dec. 7, 2022. In full satisfaction and settlement of the debt, the company will issue an aggregate of 6,008,883 common shares in the capital of the company at a deemed price of 45 cents per debt share. The debt shares issued in connection with the debt settlement will be subject to a statutory four-month-and-one-day hold period, in accordance with the policies of the Canadian Securities Exchange and applicable Canadian securities laws. The issuance of the debt shares and the completion of the debt settlement are subject to certain conditions as set forth in the debt settlement agreement.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch), and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity. With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

We seek Safe Harbor.